Navigation Links
Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team

CAMBRIDGE, Mass., April 26 /PRNewswire/ -- Satori Pharmaceuticals Incorporated, a privately held developer of therapeutics for Alzheimer's disease, today announced the election of Steven Holtzman to Chair of its Board of Directors and the appointment of Jeff Jonker as its Chief Business Officer.

Steven Holtzman, the Executive Chair and co-founder of Infinity Pharmaceuticals, recently joined the Satori Board of Directors and has now agreed to assume the role of Chair.  Steve will work closely with Satori CEO Jeff Ives and Satori's management team to continue to build a leading Alzheimer's drug discovery company.

Jeff Jonker has recently joined Satori as its CBO to further strengthen the leadership of Satori and provide expertise in developing and executing on Satori's corporate strategy.  Jeff will be responsible for managing the Company's business functions, including corporate and business development.

"We are excited to have Jeff join as another important addition to our team," said Dr. Ives.  "Jeff has an impressive record of building successful companies and establishing strong collaborations.  Strategic partners will be significant to us as we continue to grow Satori into a leading Alzheimer's disease drug discovery company, and Jeff will be a key catalyst for forming those partnerships."

Jeff brings a broad range of industry and deal experience to Satori.  Jeff was most recently Vice President of Business Development and Strategic Planning for Gloucester Pharmaceuticals (acquired by Celgene).  Previously, Jeff served seven years with Genentech in increasing positions of responsibility within both the Business Development and Corporate Legal groups, most recently as Group Director for Business Development and a member of Genentech's Immunology leadership team.  Prior to Genentech, Jeff spent six years as an attorney in the Technology Transactions Group of Wilson, Sonsini, Goodrich & Rosati, representing private and public company clients in both the life science and high tech industries.  Jeff holds degrees from Columbia University, the University of St. Andrews, and Claremont McKenna College.

"It is a privilege to join Satori's team of world leaders in the field of Alzheimer's research and drug discovery," said Mr. Jonker. "Satori's flagship program focuses on the most compelling target for preventing the progression of Alzheimer's using innovative therapeutic approaches.  I am especially impressed by the strong commitment of Satori's management, investors, and scientific advisors to building a company that will have a dramatic impact on this devastating disease."

Jeff joins Ives and Satori's leadership team including: Dr. Brian S. Bronk, Vice President of Chemistry, a former senior neuroscience research leader at Pfizer; Dr. Kevin Pojasek, Executive Director of Development, former head of Development at Solace Pharmaceuticals; and Dr. Barbara Tate, Vice President of Biology, recently a Research Fellow and Senior Director of neuroscience biology at Pfizer.

Alzheimer's disease is a debilitating disorder characterized by the progressive loss of memory, thought and language.  More than 5.2 million people in the US alone suffer from Alzheimer's disease and it is estimated that this form of dementia strikes more than 1 in 8 adults in the US over the age of 65 years.  By 2050, it is estimated that the number of new cases each year will double in the US to greater than 959,000.  Available therapies provide only temporary symptomatic relief.

About Satori™ Pharmaceuticals

Satori Pharmaceuticals is committed to the development of disease modifying therapies for Alzheimer's disease through innovative approaches that selectively target the key neurotoxic mediators and pathways of this debilitating neurodegenerative disorder.

Satori ( was founded in 2005 by Dr. Mark Findeis and PureTech Ventures and is guided by a world renowned group of advisors including Dennis Selkoe, M.D., the Vincent and Stella Coates Professor of Neurologic Diseases at the Brigham and Women's Hospital, an affiliate of Harvard Medical School; Donald Price, M.D., Professor of Pathology, Neurology, and Neuroscience and Vice Chair for Research in the Department of Pathology and Director of the Division of Neuropathology at The Johns Hopkins University School of Medicine; Christopher Eckman, Ph.D., Director for Research and Academic Affairs, MidAtlantic Neonatology and Atlantic Neonatal Research Institute Atlantic Health Systems and Professor of NeuroScience at the Mayo Clinic; David Holtzman, M.D., Andrew B. and Gretchen P. Jones Professor of Neurology and Molecular Biology & Pharmacology at the Washington University School of Medicine in St. Louis; and Paul J. Reider, Ph.D., a faculty member in the department of  chemistry at Princeton University and a former senior leader of R&D at Amgen and Merck.

Satori successfully closed a $22M Series B round of financing in early 2009 with a leading investment syndicate of InterWest Partners, New Enterprise Associates and Prospect Venture Partners.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Satori Pharmaceuticals does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE Satori Pharmaceuticals Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/24/2015)... Diego -based Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development, production and dispensing of novel compounded pharmaceuticals.  ... segments including ophthalmology, urology, sinus and integrative medicine.  ... from four facilities located in California ... New Jersey and Pennsylvania.  For ...
(Date:11/24/2015)... Nov. 24, 2015  Freudenberg Medical has developed specialty tubing ... outside of medical facilities. Africa ... care is sparse. Nevertheless, prompt diagnosis is important to treat ... the virus. With the help of a portable mini-lab or ... to village in affected areas and perform rapid testing for ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... 2015 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy is ... of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the corner, holiday travel ... help protect your family and vehicle. , According to the National Highway Traffic Safety ... Amica is sharing the following safety tips from the NHTSA: , ...
Breaking Medicine News(10 mins):